Introduction Oscotec, Inc. specializes in creating, producing, and marketing pharmaceutical goods. The corporation is organized into two primary sectors: the development of novel medications and the production of medical supplies. Their offerings encompass a range of therapeutics for osteoporosis, arthritis, periodontitis, and cancer, in addition to components for functional foods, dental bone graft materials, membranes, and other dental equipment. The company was established on December 8, 1998 and maintains its headquarters in Seongnam-si, South Korea. |
Disease Domain | Count |
---|---|
Neoplasms | 3 |
Nervous System Diseases | 1 |
Immune System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Antisense oligonucleotides | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism Syk inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TAU inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism FLT3 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Jan 2024 |
Sponsor / Collaborator Adel, Inc. [+1] |
Start Date25 Jan 2022 |
Sponsor / Collaborator |
Start Date10 Aug 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Cevidoplenib ( Syk ) | Rheumatoid Arthritis More | Phase 2 |
SKI-G-801 ( FLT3 ) | Advanced Malignant Solid Neoplasm More | Phase 1 |
ADEL-Y01 ( TAU ) | Alzheimer Disease More | IND Approval |
GNS-3595 ( ROCK2 ) | Idiopathic Pulmonary Fibrosis More | Preclinical |
OCT-3598 ( EP2 x EP4 ) | Solid tumor More | Preclinical |